Abstract: The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions where modulation of sortilin activity is beneficial.

Abstract: The present invention relates to the use of sortilin antagonists, in particular compounds of Formula (I), (II), (III), and (IV), in the treatment or prevention of hearing loss. Also provided are pharmaceutical compositions comprising the sortilin antagonists herein disclosed and methods for the treatment or prevention of hearing loss in a subject in need thereof.

Abstract: The invention provides composition comprising a fragment, derivative or variant of sortilin, or a sortilin mimetic, for use in medicine, wherein the sortilin mimetic is not SorCS1, SorCS2, SorCSS or SorLA. The composition preferably for use in treating or preventing diabetes mellitus, insulin resistance, obesity, metabolic disorders, polycystic ovary syndrome, non-alcoholic fatty liver disease, retinopathy, neuropathy, nephropathy, Alzheimer's disease and/or cardiovascular disease in a subject in need thereof. Also provided are isolated polypeptides, nucleic acids encoding the polypeptides, vectors, host cells and expression systems containing the nucleic acids and methods for making the polypeptides.

Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of abnormal plasma lipid concentrations and associated diseases and/or disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.

Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of abnormal plasma lipid concentrations and associated diseases and/or disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.

Abstract: The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for use in a method of reducing appetite, and/or for promoting weight loss, and/or for treating obesity, and/or for increasing metabolism, and/or for increasing thermogenesis, and/or for converting white fat into brown fat